Rosuvastatin for Primary Prevention Among Individuals With Elevated High-Sensitivity C-Reactive Protein and 5% to 10% and 10% to 20% 10-Year Risk: Implications of the Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial for "Intermediate Risk"

P. M Ridker, J. G MacFadyen, B. G Nordestgaard, W Koenig, J. J. P Kastelein, J Genest and R. J. Glynn

Circulation: Cardiovascular Quality and Outcomes 3 ( 5 ): 447 - 452 , 2010